SCHV vs XBI
Schwab US Large-Cap Value ETF vs SPDR S&P Biotech ETF
- • SCHV has the lower expense ratio at 0.04% vs 0.35% for XBI.
- • SCHV pays a higher dividend yield (1.75%).
Side-by-side metrics
| Metric | SCHV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.04% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.75% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $15.93B | $10.73B |
YTD return | 16.15% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.76 | 1.10 |
P/E ratio | 22.31 | — |
Last price | $34.32 | $164.28 |
Inception | — | — |
Issuer | Schwab | State Street |
SCHV top holdings
| MU | Micron Technology Inc | 4.02% |
| BRK-B | Berkshire Hathaway Inc Class B | 2.83% |
| JPM | JPMorgan Chase & Co | 2.75% |
| INTC | Intel Corp | 1.94% |
| JNJ | Johnson & Johnson | 1.94% |
| XOM | Exxon Mobil Corp | 1.76% |
| AMAT | Applied Materials Inc | 1.72% |
| LRCX | Lam Research Corp | 1.60% |
| WMT | Walmart Inc | 1.57% |
| CAT | Caterpillar Inc | 1.48% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About SCHV
SCHV (Schwab US Large-Cap Value ETF) is Large-cap US value at low cost. Managed by Schwab, the fund carries $15.9B in assets under management, an expense ratio of 0.04%, a dividend yield of 1.75%. Its largest holding is Micron Technology Inc (MU), which represents 4.0% of the portfolio. Real Estate is the fund's largest sector exposure at 3.9%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.